Canine Adenovirus (Infectious Hepatitis)
Canine Adenovirus (Infectious Hepatitis)
Canine Adenovirus (Infectious Hepatitis) refers to a viral disease and the vaccine components used to prevent it in dogs. This category helps veterinary buyers compare combination formulas, single‑antigen options, and supporting supplies like diluents and syringes for accurate dosing. Many products reflect cross‑border supply models with US shipping from Canada, and stock can change by brand, lot, and pack size without notice. You can review common schedules, compare storage needs, and identify brands suited to clinic or shelter settings.
Canine Adenovirus (Infectious Hepatitis)
Infectious canine hepatitis is primarily caused by canine adenovirus type 1 (CAV‑1), which targets the liver, eyes, and endothelium. Most modern vaccines use CAV‑2 strains to stimulate cross‑protection while reducing post‑vaccination corneal edema risk. Core immunization typically starts in puppy series and continues with boosters based on risk, age, and prior immunity. For clinical context, the Merck Veterinary Manual provides an overview of disease signs and transmission in dogs with concise clinical guidance for practitioners.
Clinic teams consider patient history, exposure risk, and maternal antibody interference when scheduling series and boosters. Modified‑live vaccine (MLV) formulations are common for combination products, balancing robust immunity with practical handling. When uncertain about prior exposure, some teams use antibody measurement (titer) to inform timing. Keep in mind that local regulations, shelter intake protocols, and traveling pet needs can shift recommended intervals. Always align handling and use with manufacturer instructions and veterinary standards for safe administration.
What’s in This Category
This category includes combination biologics that cover distemper, adenovirus, and parvovirus, sometimes with parainfluenza and leptospirosis. It also features single‑dose vials for individual dogs and multi‑dose vials for high‑throughput settings. You will see cold‑chain shippers, reconstitution diluents, and labeled needles or syringes for weight‑based dosing. A typical listing outlines antigens covered, dosage per vial, and required diluent volumes for proper reconstitution and injection.
Products may reference Canine adenovirus vaccine components derived from CAV‑2 and used within broader canine combo schedules. Some lines are preservative‑free; others specify thimerosal content. Many products are intended for subcutaneous administration; package inserts clarify the route. Storage usually requires 2–7°C refrigeration and avoidance of freezing to maintain potency. Listings may also note color change upon mixing, recommended discard time for open multi‑dose vials, and carton‑level traceability details like lot and expiry.
How to Choose
Start with your patient population and workflow. High‑volume shelters may prefer multi‑dose vials with shorter draw times. Small practices often choose single‑dose units to reduce waste and simplify charting. Consider antigen scope, since some combinations add parainfluenza or leptospirosis to address regional risks. If you serve travelers or boarding facilities, align with certificate requirements and local expectations.
Protocol fit matters as much as labeling. Many clinics standardize on DA2PP vaccine timing within puppy series, then fold in risk‑based components like leptospirosis later. Compare manufacturer support materials, titer interpretation guidance, and packaging that fits your refrigerator layout. Review needle gauge and recommended sites, and coordinate staff training to keep technique consistent and safe.
- Common mistake: choosing a combo that overlaps with a separate lepto plan, causing duplication.
- Common mistake: underestimating cold‑chain space for multi‑dose cartons, leading to crowding.
- Common mistake: mixing brands mid‑series without checking equivalency and antigen coverage.
Popular Options
Many clinics rely on well‑established combo lines with clear labeling, sturdy packaging, and predictable handling. A representative example is Nobivac DAPPv, used for core immunization in puppies and adult dogs following established schedules. Teams value broad field use, consistent package inserts, and compatibility with typical cold‑chain setups. It fits well where staff rotate between exam rooms and treatment areas.
Other practices choose the Vanguard DAPP series for clinics that emphasize standardized protocols across multiple locations. These lines often feature clear carton coding, reliable diluent pairing, and concise charts for timing. Some teams prefer Duramune Max-5 when they want a familiar core combination with straightforward reconstitution steps. Each option addresses similar indications, so selection often hinges on training materials, vendor reliability, and how cartons fit your storage.
Related Conditions & Uses
Core dog vaccines are grouped because they protect against severe, widespread diseases with significant health impacts. Adenovirus prevention aligns closely with distemper and parvovirus protocols, especially in high‑risk communities and shelters. Where aerosol or kennel‑type exposures occur, clinicians may also discuss parainfluenza as part of a broader respiratory plan. Protocols should reflect local disease prevalence and intake profiles.
Many teams also consider leptospirosis where wildlife exposure, flooding, or rodent activity is common. Traveling pets, show dogs, and working animals may need documentation that aligns with regional boarding or event rules. When previous records are uncertain, titer testing can help inform timing while a series is completed. Clear charting, appointment spacing, and careful storage help maintain the continuity needed for durable immunity across a patient’s life.
Authoritative Sources
For evidence‑based guidance on canine vaccination schedules, see the AAHA Canine Vaccination Guidelines covering core recommendations and updates. Clinical disease context for infectious canine hepatitis is summarized by the Merck Veterinary Manual with signs, transmission, and management. Regulatory information on veterinary biologics is available from USDA Center for Veterinary Biologics including licensing and compliance.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.
Filter
Product price
Product categories
Conditions
Select options
This product has multiple variants. The options may be chosen on the product page
Frequently Asked Questions
Do these vaccines cover CAV-1 even if they list CAV-2?
Yes. Most modern canine combinations use a CAV-2 component that provides cross‑protection against CAV‑1. Labels and datasheets describe the antigens, route, and dosage. If prior records are unclear, your team can review timing and consider antibody testing. Always follow the manufacturer’s insert for handling, storage, and administration.
Can I mix brands during a puppy series if stock changes?
Sometimes. Many clinics try to keep the series consistent, but practical realities occur. When switching, confirm antigen equivalence, dosing intervals, and formulation type. Keep records precise so staff can track any changes. If a product swap is necessary, review the next dose timing and observe for expected post‑vaccination responses.
What storage conditions are typical for these biologics?
Most products require refrigeration between 2–7°C and protection from light. Avoid freezing, and do not use expired vials. Once reconstituted, observe the labeled time window for use and discard. Plan refrigerator space around carton size and multi‑dose constraints. Keep validated thermometers and record logs to support reliable cold‑chain management.
How do multi-dose vials fit high-volume clinics or shelters?
Multi‑dose vials can reduce waste and speed workflows in intake settings. They require careful aseptic technique, accurate logging, and timely use after reconstitution. Some teams standardize needle changes between draws and monitor open‑vial time closely. If patient flow is unpredictable, single‑dose units may better match staffing and reduce leftover doses.
Can titers help decide booster timing for adult dogs?
Yes. Antibody titers can help assess existing immunity when records are uncertain. They do not replace clinical judgment or local risk assessment. Use results alongside exposure history and program goals, such as travel or boarding. Discuss interpretation limits with your veterinarian, especially for pathogens with varied correlates of protection.